Related Experiment Video

Updated: Aug 8, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial

Fatma Taneli1, Selma Yegane, Cevval Ulman

  • 1Department of Biochemistry and Clinical Biochemistry, Celal Bayar University, Faculty of Medicine, Manisa, Turkey. fatma.taneli@bayar.edu.tr

Angiology
|May 17, 2006
PubMed

Insights

Serum leptin concentrations were elevated in patients with chronic stable angina pectoris (CSAP) and ST-elevated myocardial infarction (STEMI). These findings suggest leptin may be an independent risk factor for ischemic heart disease (IHD).

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Leptin, an adipocytokine primarily from adipose tissue, is present in atherosclerotic lesions.
  • The association between serum leptin levels and ischemic heart disease (IHD) remains unclear.
  • This study investigates leptin's role in IHD, specifically in ST-elevated myocardial infarction (STEMI) and chronic stable angina pectoris (CSAP).

Purpose of the Study:

  • To compare serum leptin concentrations in patients with CSAP and STEMI versus controls.
  • To evaluate correlations between leptin and established atherosclerotic risk factors.
  • To determine if leptin is an independent risk factor for IHD.

Main Methods:

  • Prospective study involving 35 CSAP patients, 40 STEMI patients, and 30 controls.
  • Measurements included serum leptin, high-sensitivity C-reactive protein (Hs-CRP), homocysteine, and fibrinogen.
  • Coronary angiography was used to confirm normal findings in the control group.

Main Results:

  • Serum leptin levels were significantly higher in both CSAP and STEMI groups compared to controls.
  • Serum homocysteine levels were elevated in both CSAP and STEMI patients versus controls.
  • Serum fibrinogen levels were significantly increased only in the CSAP group.

Conclusions:

  • Elevated serum leptin concentrations are observed in patients with CSAP and STEMI.
  • No significant correlation was found between leptin and classical risk factors (Hs-CRP, homocysteine, fibrinogen).
  • Leptin may represent an independent risk factor for IHD, warranting further investigation into its pathophysiological role.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...